↓ Skip to main content

“…still waiting for chloroquine”: the challenge of communicating changes in first-line treatment policy for uncomplicated malaria in a remote Kenyan district

Overview of attention for article published in Malaria Journal, July 2014
Altmetric Badge

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
74 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
“…still waiting for chloroquine”: the challenge of communicating changes in first-line treatment policy for uncomplicated malaria in a remote Kenyan district
Published in
Malaria Journal, July 2014
DOI 10.1186/1475-2875-13-258
Pubmed ID
Authors

Vincent Okungu, Lucy Gilson

Abstract

Widespread parasite resistance to first-line treatment for uncomplicated malaria leads to introduction of new drug interventions. Introducing such interventions is complex and sensitive because of stakeholder interests and public resistance. To enhance take up of such interventions, health policy communication strategies need to deliver accurate and accessible information to empower communities with necessary information and address problems of cultural acceptance of new interventions.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 4%
United States 3 4%
Burkina Faso 1 1%
South Africa 1 1%
Unknown 66 89%

Demographic breakdown

Readers by professional status Count As %
Student > Master 16 22%
Researcher 13 18%
Student > Doctoral Student 6 8%
Other 5 7%
Student > Ph. D. Student 5 7%
Other 11 15%
Unknown 18 24%
Readers by discipline Count As %
Medicine and Dentistry 18 24%
Nursing and Health Professions 13 18%
Social Sciences 6 8%
Agricultural and Biological Sciences 4 5%
Economics, Econometrics and Finance 3 4%
Other 10 14%
Unknown 20 27%